Outsourcing-Pharma.com compiles the news that has featured in the clinical contract community of late involving Clinsys, Averion, PRA International and others.
Biomoda has enlisted Averion International to provide a range of clinical services including protocol design and study implementation for its clinical programs.
The firm is attempting to bring to market an early lung cancer detection testing technology, based on a porphyrin application that preferentially binds to cancerous or aberrant cells extracted from lung sputum samples, which then glow red under fluorescent light to allow detection under a microscope.
Recently Clinsys Clinical Research has announced the relocation of its headquarters to a new facility in Bedminster, New Jersey to accommodate its future growth plans. The firm has also recently expanded its operations in Raleigh, North Carolina and Dusseldorf, Germany.
Meanwhile, US Federal antitrust regulators have given the green light to a $745m takeover bid by private equity firm Genstar Capital, for PRA International. The deal is now is expected to close in the fourth quarter.
In other clinical movements, Canadian contract research organisation (CRO) ethica Clinical Research has formed a partnership with US Institutional Review Board (IRB) services firm Clinical Research Review (CRRI) to deliver collaborative research ethics review services for clinical research conducted both in the US and Canada.
"This collaboration will allow sponsors to place research with one independent, central review body with a high degree of confidence that timely and compliant oversight will occur," commented Dr Felix Khin-Maung-Gyi, founder and CEO of CRRI.
In addition, Russian CRO Synergy Research Group has ventured into India striking up an alliance with a CRO based in New Delhi called Neeman Medical International.
Together the firms will provide international sponsors with monitoring and site and data management services from Neeman's 70 investigative sites in 17 locations within India.
In August, Synergy formed a similar alliance with US CRO Promedica International and the ambitious firm said it now has its sights firmly set on finding a partner in China.
"We've recently taken part in the Russian-Chinese Forum on biotechnological and pharmaceutical industries, and have established a number of good promising contacts," said Igor Stefanov, director of business development at Synergy.
Meanwhile, US CRO United BioSource Corporation (UBC) recently purchased a slice of German CRO ClinResearch, giving the firm a new capability in adaptive clinical trials.